Left Heart Disease Phenotype in Pulmonary Arterial Hypertension: Considerations for Therapy
- PMID: 38599749
- DOI: 10.1016/j.chest.2023.11.027
Left Heart Disease Phenotype in Pulmonary Arterial Hypertension: Considerations for Therapy
Conflict of interest statement
Financial/Nonfinancial Disclosures The authors have reported to CHEST the following: T. T. served as consultant to United Therapeutics, J&J, Merck, and Aria CV, and receives research funding from Aria CV, Tenax Therapeutics, and Merck for clinical research through the University of Minnesota. None declared. (N. A.-N.).
Comment on
-
Impact of Left Heart Disease Risk Factors on Outcomes in Pulmonary Arterial Hypertension Therapy.Chest. 2024 Apr;165(4):967-977. doi: 10.1016/j.chest.2023.10.037. Epub 2023 Nov 10. Chest. 2024. PMID: 37951349
References
Publication types
MeSH terms
Grants and funding
LinkOut - more resources
Full Text Sources
Medical
